Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
会议论文期刊论文
Domchek Susan M.,Robson Mark,Im Seock-Ah, et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD [J].CANCER RESEARCH,2018,78(4).
APA：
Domchek Susan M.,Robson Mark,Im Seock-Ah,Senkus Elzbieta,&Tung Nadine.(2018).Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD .CANCER RESEARCH,78(4).
MLA：
Domchek Susan M., et al. "Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD" .CANCER RESEARCH 78,4(2018).
Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
Univ Penn, Philadelphia, PA 19104 USA. Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. Seoul Natl Univ, Seoul Natl Univ Hosp, Canc Res Inst, Coll Med, Seoul, South Korea. Med Univ Gdansk, Gdansk, Poland. Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, Beijing, Peoples R China. Peking Union Med Coll, Beijing, Peoples R China. Osaka Natl Hosp, Natl Hosp Org, Osaka, Japan. Inst Gustave Roussy, Villejuif, France. Jilin Univ, Hosp 1, Changchun, Jilin, Peoples R China. Univ Manchester, Christie Hosp NHS Fdn Trust, Manchester, Lancs, England. Univ Manchester, Fac Biol Med & Hlth, Manchester, Lancs, England. Univ Padua, Padua, Italy. Ist Oncol Veneto IRCCS, Padua, Italy. AstraZeneca, Cambridge, England. AstraZeneca, Gaithersburg, MD USA. AstraZeneca, Macclesfield, Cheshire, England. Dana Farber Harvard Canc Ctr, Beth Israel Deaconess Med Ctr, Boston, MA USA.
(8.0+极速模式)